Amivantamab-lazertinib ups survival in EGFR-mutated advanced lung cancer
by Elana GotkineFor patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved progression-free survival compared with osimertinib as first-line tre
Updated on: July 08,2024
0

Amivantamab-lazertinib ups survival in EGFR-mutated advanced lung cancer
by Elana GotkineFor patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved progression-free survival compared with osimertinib as first-line tre
Updated on:July 08,2024
0
